Drug Trial Radar · NCT07931261
[18F]FET PET for Differentiating Tumor Progression vs Treatment-Related Changes in Brain Metastases
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
381
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Apr 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study will evaluate whether \[18F\]Floretyrosine (\[18F\]FET) PET imaging can help distinguish active brain tumor growth from treatment-related changes in patients with brain metastases who have unclear MRI findings after treatment. The study has two parts. Part 1 will identify the lowest effective dose of \[18F\]FET PET that provides reliable imaging results. Part 2 will evaluate the accuracy of \[18F\]FET PET, using the optimized dose, for distinguishing tumor progression from treatment-related changes. Study results will be compared with information from follow-up imaging, clinical assessments, and, when available, tissue samples obtained during routine clinical care. The goal is to determine whether \[18F\]FET PET can improve diagnostic accuracy and support clinical decision-making for patients with brain metastases.
Conditions
- Brain Metastasis
- Radiation Necrosis
- Pseudoprogression
- Tumor Progression
Interventions
Floretyrosine F 18 ([18F]FET)Drug
Floretyrosine F 18 (\[18F\]FET) is an investigational amino acid positron emission tomography (PET) radiopharmaceutical administered as a single intravenous injection for diagnostic imaging. Participants in Part 1 receive 740 MBq (±10%) of \[18F\]FET to evaluate dose optimization through comparison of reconstructed reduced-dose and full-dose PET images. Participants in Part 2 receive \[18F\]FET at the optimized dose identified in Part 1 to evaluate its diagnostic performance for differentiating tumor progression from treatment-related changes in brain metastases with equivocal MRI findings following therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient-Level Mean Dice Similarity Coefficient for Lesion Spatial Agreement Between Reduced-Dose and Full-Dose [18F]FET PET ImagesTime frame: From Day 1 through Day 2 (±1 day) follow-up
- Sensitivity of [18F]FET PET for Distinguishing Tumor Progression From Treatment-Related Changes Compared With CSOTTime frame: From baseline Day 1 through CSOT determination (approximately 2-3 months).
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.